1. Home
  2. ELA vs CHRS Comparison

ELA vs CHRS Comparison

Compare ELA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELA
  • CHRS
  • Stock Information
  • Founded
  • ELA 1965
  • CHRS 2010
  • Country
  • ELA United States
  • CHRS United States
  • Employees
  • ELA N/A
  • CHRS N/A
  • Industry
  • ELA Consumer Specialties
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ELA Consumer Discretionary
  • CHRS Health Care
  • Exchange
  • ELA Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • ELA 156.2M
  • CHRS 84.2M
  • IPO Year
  • ELA N/A
  • CHRS 2014
  • Fundamental
  • Price
  • ELA $6.08
  • CHRS $0.82
  • Analyst Decision
  • ELA Strong Buy
  • CHRS Buy
  • Analyst Count
  • ELA 1
  • CHRS 3
  • Target Price
  • ELA $9.00
  • CHRS $4.68
  • AVG Volume (30 Days)
  • ELA 69.3K
  • CHRS 1.3M
  • Earning Date
  • ELA 08-06-2025
  • CHRS 08-07-2025
  • Dividend Yield
  • ELA N/A
  • CHRS N/A
  • EPS Growth
  • ELA 15.15
  • CHRS N/A
  • EPS
  • ELA 0.28
  • CHRS N/A
  • Revenue
  • ELA $188,774,278.00
  • CHRS $272,251,000.00
  • Revenue This Year
  • ELA $7.61
  • CHRS N/A
  • Revenue Next Year
  • ELA $6.27
  • CHRS $106.56
  • P/E Ratio
  • ELA $21.59
  • CHRS $1.87
  • Revenue Growth
  • ELA 14.19
  • CHRS 19.87
  • 52 Week Low
  • ELA $4.20
  • CHRS $0.66
  • 52 Week High
  • ELA $7.88
  • CHRS $2.43
  • Technical
  • Relative Strength Index (RSI)
  • ELA 53.47
  • CHRS 53.13
  • Support Level
  • ELA $5.68
  • CHRS $0.72
  • Resistance Level
  • ELA $6.21
  • CHRS $0.77
  • Average True Range (ATR)
  • ELA 0.29
  • CHRS 0.04
  • MACD
  • ELA 0.05
  • CHRS 0.01
  • Stochastic Oscillator
  • ELA 78.33
  • CHRS 91.62

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: